NKTX
Nkarta, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-05-12 |
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Enrollment ongoing at 4 billion cell dose level (12 billion cells in 3-dose cycle) across all indications in Ntrust-1 and Ntrust-2 Regulatory agreement supports expansion into community-based settings with outpatient dosing to reduce patient burden Initial clinical data from Ntrust-1 and Ntrust-2 |
| 2026-04-15 |
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
Expanded treatment in community settings will reduce patient burden Option to redose patients granted in both Ntrust-1 and Ntrust-2 studies Rheumatoid arthritis cohort to be added to Ntrust-2 Dosing continues at 4 billion cell dose level (12 billion cells in 3-dose cycle) with initial data expected |
| 2026-04-09 |
Nkarta to Participate in Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the 25th Annual Needham Virtual |
| 2026-03-25 |
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Dose escalation for NKX019 advanced to 4 billion cells per dose on days 0, 3 and 7 for a total of 12 billion cells per cycle Initial clinical data from Ntrust-1 and Ntrust-2 targeted for presentation at a medical conference in 2026 Cash balance of $295.1 million on December 31, 2025, including |
| 2026-02-27 |
Nkarta to Participate in March Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: |
| 2025-12-02 |
Nkarta to Participate in Evercore Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8 th Annual Healthcare |
| 2025-11-10 |
Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamide Enrollment streamlined |
| 2025-10-30 |
Nkarta to Participate in November Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare |
| 2025-10-22 |
Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the |
| 2025-09-02 |
Nkarta to Participate in a September Investor Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-30 | H.C. Wainwright 4th Annual Cell Therapy Virtual Conference | Conference |
| 2026-04-15 | 25th Annual Needham Virtual Healthcare Conference | Conference |
| 2026-03-10 | Leerink Global Healthcare Conference | Conference |
| 2026-03-02 | TD Cowen 46th Annual Health Care Conference | Conference |
| 2025-12-04 | Evercore Healthcare Conference in Miami | Conference |
| 2025-11-13 | TD Cowen Immunology & Inflammation Summit | Event |
| 2025-11-12 | Stifel 2025 Healthcare Conference | Conference |
| 2025-09-09 | H.C. Wainwright 27th Annual Global Investment Conference | Conference |
| 2025-07-30 | H.C Wainwright “HCW@Home with Nkarta, Inc.” | Event |
| 2025-04-08 | 24th Annual Needham Virtual Healthcare Conference | Conference |
| 2025-03-10 | Leerink Partners 2025 Global Healthcare Conference | Conference |
Source: https://ir.nkartatx.com/